Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination

Suman Das, Janmejay Singh, Heena Shaman, Balwant Singh, Anbalagan Anantharaj, Patil Sharanabasava, Rajesh Pandey, Rakesh Lodha, Anil Kumar Pandey and Guruprasad R. Medigeshi ()
Additional contact information
Suman Das: Employees State Insurance Corporation Medical College and Hospital
Janmejay Singh: Translational Health Science and Technology Institute
Heena Shaman: Translational Health Science and Technology Institute
Balwant Singh: Translational Health Science and Technology Institute
Anbalagan Anantharaj: Translational Health Science and Technology Institute
Patil Sharanabasava: Translational Health Science and Technology Institute
Rajesh Pandey: INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology
Rakesh Lodha: All India Institute of Medical Sciences
Anil Kumar Pandey: Employees State Insurance Corporation Medical College and Hospital
Guruprasad R. Medigeshi: Translational Health Science and Technology Institute

Nature Communications, 2022, vol. 13, issue 1, 1-7

Abstract: Abstract Many adults in India have received at least one dose of COVID-19 vaccine with or without a prior history SARS-CoV-2 infection. However, there is limited information on the effect of prior immunity on antibody response upon vaccination in India. As immunization of individuals continues, we aimed to assess whether pre-existing antibodies are further boosted by a single dose of BBV152, an inactivated SARS-CoV-2 vaccine, and, if these antibodies can neutralize SARS-CoV-2 Delta and Omicron variants. Here we show that natural infection during the second wave in 2021 led to generation of neutralizing antibodies against other lineages of SARS-CoV-2 including the Omicron variant, albeit at a significantly lower level for the latter. A single dose of BBV152 boosted antibody titers against the Delta and the Omicron variants but the antibody levels remained low against the Omicron variant. Boosting of antibodies showed negative correlation with baseline neutralizing antibody titers.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-31170-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31170-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-31170-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().